comparemela.com
  1. Home
  2. Live Updates
  3. InnoCare Announces Phase II Study Results of TYK2 Inhibitor ICP-332 Meet Primary Endpoint in Patients with Atomic Dermatitis : comparemela.com

InnoCare Announces Phase II Study Results of TYK2 Inhibitor ICP-332 Meet Primary Endpoint in Patients with Atomic Dermatitis

InnoCare Announces Phase II Study Results of TYK2 Inhibitor ICP-332 Meet Primary Endpoint in Patients with Atomic Dermatitis

streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Related Keywords

China , Nanjing , Jiangsu , Shanghai , Hong Kong , United States , Guangzhou , Guangdong , Beijing , Chunhua Lu , Innocare Pharma , Jasmine Cui , Care Pharma , Tyrosine Kinase , Eczema Area , Severity Index , Global Assessment , Pharma Intelligence ,

© 2024 Vimarsana

comparemela.com © 2020. All Rights Reserved.